Jump to content
RemedySpot.com

3 New HCV abstracts

Rate this topic


Recommended Posts

Posted

J Hepatol. 2010 Dec 10. [Epub ahead of print]

IL28B inhibits Hepatitis C virus replication through the JAK-STAT pathway.

Zhang L, Jilg N, Shao RX, Lin W, Fusco DN, Zhao H, Goto K, Peng LF, Chen WC,

Chung RT.

Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital,

Harvard Medical School, Boston, MA.

Abstract

BACKGROUND AND AIMS: The combination of pegylated interferon (IFN) α and

ribavirin (RBV) is standard therapy for patients with chronic HCV infection.

However, it produces a sustained virologic response (SVR) in only half of

treated individuals and is associated with significant side effects. Recently

several single-nucleotide polymorphisms (SNPs) near the IL28B locus, also known

as IFNλ3, were identified to be strong predictors of SVR in patients receiving

PEG-IFN and RBV. We sought to determine whether IL28B was capable of inhibiting

HCV replication and to determine the pathway by which IL28B exhibits anti-HCV

activity.

METHODS: Using the full-length HCV replicon OR6 and the infectious HCV clones

JFH1 and Jc1, we assessed the anti-HCV effect of IL28B on HCV and characterized

the key steps of the JAK-STAT pathway by real time PCR, luciferase assay, and

Western blot. Finally, we evaluated the anti-HCV effect of IL28B in the presence

of JAK-STAT pathway inhibitors such as blocking antibodies, a pharmacological

inhibitor and siRNAs.

RESULTS: We found that IL28B inhibits HCV replication in a dose- and time-

dependent manner. Like IFNα, IL28B induces the phosphorylation of STAT1 and

STAT2, ISRE-driven transcription, and expression of known ISGs. The anti-HCV

effects of IL28A, IL28B and IL29 were abrogated by an IL10R2 blocking antibody,

a pharmacological inhibitor of JAK1/TYK2, and by siRNA against IL28R1, STAT1,

STAT2 and IRF9.

CONCLUSIONS: Our data demonstrate that IL28A, IL28B and IL29 signal through the

JAK-STAT pathway to inhibit HCV. These data suggest possible applications of new

approaches in HCV treatment.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21147189 [PubMed - as supplied by publisher]

Related citations

J Hepatol. 2010 Dec 10. [Epub ahead of print]

Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus

liver graft reinfection.

Lange CM, Moradpour D, Doehring A, Lehr HA, Müllhaupt B, Bibert S, Bochud PY,

Antonino AT, Pascual M, Farnik H, Shi Y, Bechstein WO, Moench C, Hansmann ML,

Sarrazin C, Lötsch J, Zeuzem S, Hofmann WP.

Medizinische Klinik 1, Germany; Centre Hospitalier Universitaire Vaudois,

University of Lausanne, Rue Bugnon 46, CH-1010 Lausanne, Switzerland.

Abstract

BACKGROUND AND AIM: Recent studies described a major impact of genetic

variations near the IL28B gene on the natural course and outcome of antiviral

therapy in chronic hepatitis C. We therefore aimed to explore the impact of

donor and recipient genotypes of these polymorphisms on hepatitis C virus (HCV)

liver graft reinfection.

METHODS: Donor and recipient genotypes of IL28B rs12979860C>T single nucleotide

polymorphism were determined in 91 patients with HCV liver graft reinfection, 47

of which were treated with pegylated interferon-α(PEG-IFN-α) and ribavirin.

IL28B genetic polymorphisms were correlated with the natural course and

treatment outcome of recurrent hepatitis C.

RESULTS: Patients requiring liver transplantation due to end-stage chronic

hepatitis C appeared to be selected towards the adverse genotypes

rs12979860CT/TT compared to non-transplanted HCV-infected patients (p=0.046).

Patients with the donor genotype rs12979860CC had higher peak ALT and HCV RNA

serum concentrations than those with CT/TT (p=0.04 and 0.06, respectively). No

associations were observed between ALT / HCV RNA serum concentrations and

recipient genotypes (p>0.3). More important, donor IL28B rs12979860 CC vs. CT/TT

genotypes were associated with rapid, complete early, and sustained virologic

response (RVR, cEVR, SVR) to treatment with PEG-IFN-α and ribavirin (p=0.003,

0.0012, 0.008, respectively), but weaker associations of recipient genotypes

with RVR, cEVR and SVR were observed as well (p=0.0046, 0.115, 0.118,

respectively).

CONCLUSIONS: We provide evidence for a dominant, but not exclusive impact of the

donor rather than the recipient IL28B genetic background on the natural course

and treatment outcome of HCV liver graft reinfection.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21147186 [PubMed - as supplied by publisher]

Related citations

J Hepatol. 2010 Sep 29. [Epub ahead of print]

HIV infection increases HCV-induced hepatocyte apoptosis.

Jang JY, Shao RX, Lin W, Weinberg E, Chung WJ, Tsai WL, Zhao H, Goto K, Zhang L,

Mendez-Navarro J, Jilg N, Peng LF, Brockman MA, Chung RT.

Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital,

Harvard Medical School, Boston, MA 02114, USA; Institute for Digestive Research,

Digestive Disease Center, Department of Internal Medicine, College of Medicine,

Soonchunhyang University, Seoul, South Korea.

Abstract

BACKGROUND & AIMS: HCV related liver disease is one of the most important

complications in persons with HIV, with accelerated fibrosis progression in

coinfected persons compared to those with HCV alone. We hypothesized that

HCV-HIV coinfection increases HCV related hepatocyte apoptosis and that HCV and

HIV influence TRAIL signaling in hepatocytes.

METHODS: We analyzed the effect of HIV in JFH1-infected Huh7.5.1 cells.

Apoptosis was measured by Caspase-Glo 3/7 assay and Western blotting for cleaved

PARP. TRAIL, TRAIL receptor 1 (DR4), and 2 (DR5) mRNA and protein levels were

assessed by real-time PCR and Western blot, respectively. We also investigated

activation of caspase pathways using caspase inhibitors and assessed expression

of Bid and cytochrome C.

RESULTS: We found increased caspase 3/7 activity and cleaved PARP in JFH1

HCV-infected Huh7.5.1 cells in the presence of heat-inactivated HIV, compared to

Huh7.5.1 cells infected with JFH1 or exposed to heat-inactivated HIV alone. Both

DR4 and DR5 mRNA and protein expression were increased in JFH1-infected cells in

the presence of inactivated HIV compared to Huh7.5.1 cells infected with JFH1 or

exposed to heat-inactivated HIV alone. Pancaspase, caspase-8, and caspase-9

inhibition blocked apoptosis induced by HCV, inactivated HIV, and HCV plus

inactivated HIV. A caspase-9 inhibitor blocked apoptosis induced by HCV, HIV,

and HCV-HIV comparably to pancaspase and caspase-8 inhibitors. HCV induced the

activation of Bid cleavage and cytochrome C release. The addition of HIV

substantially augmented this induction.

CONCLUSIONS: Our findings indicate that hepatocyte apoptosis is increased in the

presence of HCV and HIV compared to HCV or HIV alone, and that this increase is

mediated by DR4 and DR5 up-regulation. These results provide an additional

mechanism for the accelerated liver disease progression observed in HCV-HIV

co-infection.

Copyright © 2010 European Association for the Study of the Liver. Published by

Elsevier B.V. All rights reserved.

PMID: 21146890 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Dec 10. [Epub ahead of print]

IL28B inhibits Hepatitis C virus replication through the JAK-STAT pathway.

Zhang L, Jilg N, Shao RX, Lin W, Fusco DN, Zhao H, Goto K, Peng LF, Chen WC,

Chung RT.

Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital,

Harvard Medical School, Boston, MA.

Abstract

BACKGROUND AND AIMS: The combination of pegylated interferon (IFN) α and

ribavirin (RBV) is standard therapy for patients with chronic HCV infection.

However, it produces a sustained virologic response (SVR) in only half of

treated individuals and is associated with significant side effects. Recently

several single-nucleotide polymorphisms (SNPs) near the IL28B locus, also known

as IFNλ3, were identified to be strong predictors of SVR in patients receiving

PEG-IFN and RBV. We sought to determine whether IL28B was capable of inhibiting

HCV replication and to determine the pathway by which IL28B exhibits anti-HCV

activity.

METHODS: Using the full-length HCV replicon OR6 and the infectious HCV clones

JFH1 and Jc1, we assessed the anti-HCV effect of IL28B on HCV and characterized

the key steps of the JAK-STAT pathway by real time PCR, luciferase assay, and

Western blot. Finally, we evaluated the anti-HCV effect of IL28B in the presence

of JAK-STAT pathway inhibitors such as blocking antibodies, a pharmacological

inhibitor and siRNAs.

RESULTS: We found that IL28B inhibits HCV replication in a dose- and time-

dependent manner. Like IFNα, IL28B induces the phosphorylation of STAT1 and

STAT2, ISRE-driven transcription, and expression of known ISGs. The anti-HCV

effects of IL28A, IL28B and IL29 were abrogated by an IL10R2 blocking antibody,

a pharmacological inhibitor of JAK1/TYK2, and by siRNA against IL28R1, STAT1,

STAT2 and IRF9.

CONCLUSIONS: Our data demonstrate that IL28A, IL28B and IL29 signal through the

JAK-STAT pathway to inhibit HCV. These data suggest possible applications of new

approaches in HCV treatment.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21147189 [PubMed - as supplied by publisher]

Related citations

J Hepatol. 2010 Dec 10. [Epub ahead of print]

Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus

liver graft reinfection.

Lange CM, Moradpour D, Doehring A, Lehr HA, Müllhaupt B, Bibert S, Bochud PY,

Antonino AT, Pascual M, Farnik H, Shi Y, Bechstein WO, Moench C, Hansmann ML,

Sarrazin C, Lötsch J, Zeuzem S, Hofmann WP.

Medizinische Klinik 1, Germany; Centre Hospitalier Universitaire Vaudois,

University of Lausanne, Rue Bugnon 46, CH-1010 Lausanne, Switzerland.

Abstract

BACKGROUND AND AIM: Recent studies described a major impact of genetic

variations near the IL28B gene on the natural course and outcome of antiviral

therapy in chronic hepatitis C. We therefore aimed to explore the impact of

donor and recipient genotypes of these polymorphisms on hepatitis C virus (HCV)

liver graft reinfection.

METHODS: Donor and recipient genotypes of IL28B rs12979860C>T single nucleotide

polymorphism were determined in 91 patients with HCV liver graft reinfection, 47

of which were treated with pegylated interferon-α(PEG-IFN-α) and ribavirin.

IL28B genetic polymorphisms were correlated with the natural course and

treatment outcome of recurrent hepatitis C.

RESULTS: Patients requiring liver transplantation due to end-stage chronic

hepatitis C appeared to be selected towards the adverse genotypes

rs12979860CT/TT compared to non-transplanted HCV-infected patients (p=0.046).

Patients with the donor genotype rs12979860CC had higher peak ALT and HCV RNA

serum concentrations than those with CT/TT (p=0.04 and 0.06, respectively). No

associations were observed between ALT / HCV RNA serum concentrations and

recipient genotypes (p>0.3). More important, donor IL28B rs12979860 CC vs. CT/TT

genotypes were associated with rapid, complete early, and sustained virologic

response (RVR, cEVR, SVR) to treatment with PEG-IFN-α and ribavirin (p=0.003,

0.0012, 0.008, respectively), but weaker associations of recipient genotypes

with RVR, cEVR and SVR were observed as well (p=0.0046, 0.115, 0.118,

respectively).

CONCLUSIONS: We provide evidence for a dominant, but not exclusive impact of the

donor rather than the recipient IL28B genetic background on the natural course

and treatment outcome of HCV liver graft reinfection.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21147186 [PubMed - as supplied by publisher]

Related citations

J Hepatol. 2010 Sep 29. [Epub ahead of print]

HIV infection increases HCV-induced hepatocyte apoptosis.

Jang JY, Shao RX, Lin W, Weinberg E, Chung WJ, Tsai WL, Zhao H, Goto K, Zhang L,

Mendez-Navarro J, Jilg N, Peng LF, Brockman MA, Chung RT.

Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital,

Harvard Medical School, Boston, MA 02114, USA; Institute for Digestive Research,

Digestive Disease Center, Department of Internal Medicine, College of Medicine,

Soonchunhyang University, Seoul, South Korea.

Abstract

BACKGROUND & AIMS: HCV related liver disease is one of the most important

complications in persons with HIV, with accelerated fibrosis progression in

coinfected persons compared to those with HCV alone. We hypothesized that

HCV-HIV coinfection increases HCV related hepatocyte apoptosis and that HCV and

HIV influence TRAIL signaling in hepatocytes.

METHODS: We analyzed the effect of HIV in JFH1-infected Huh7.5.1 cells.

Apoptosis was measured by Caspase-Glo 3/7 assay and Western blotting for cleaved

PARP. TRAIL, TRAIL receptor 1 (DR4), and 2 (DR5) mRNA and protein levels were

assessed by real-time PCR and Western blot, respectively. We also investigated

activation of caspase pathways using caspase inhibitors and assessed expression

of Bid and cytochrome C.

RESULTS: We found increased caspase 3/7 activity and cleaved PARP in JFH1

HCV-infected Huh7.5.1 cells in the presence of heat-inactivated HIV, compared to

Huh7.5.1 cells infected with JFH1 or exposed to heat-inactivated HIV alone. Both

DR4 and DR5 mRNA and protein expression were increased in JFH1-infected cells in

the presence of inactivated HIV compared to Huh7.5.1 cells infected with JFH1 or

exposed to heat-inactivated HIV alone. Pancaspase, caspase-8, and caspase-9

inhibition blocked apoptosis induced by HCV, inactivated HIV, and HCV plus

inactivated HIV. A caspase-9 inhibitor blocked apoptosis induced by HCV, HIV,

and HCV-HIV comparably to pancaspase and caspase-8 inhibitors. HCV induced the

activation of Bid cleavage and cytochrome C release. The addition of HIV

substantially augmented this induction.

CONCLUSIONS: Our findings indicate that hepatocyte apoptosis is increased in the

presence of HCV and HIV compared to HCV or HIV alone, and that this increase is

mediated by DR4 and DR5 up-regulation. These results provide an additional

mechanism for the accelerated liver disease progression observed in HCV-HIV

co-infection.

Copyright © 2010 European Association for the Study of the Liver. Published by

Elsevier B.V. All rights reserved.

PMID: 21146890 [PubMed - as supplied by publisher]

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...